Amitabh C. Pandey
@amitabhcpandey.bsky.social
Assistant Professor physician-scientist cardiologist, translational & clinical researcher, @tulanedom, @tulanemedicine
Always great when we can introduce new folks to #vascular biology research. @AbboudFHassan doing a great job talking about some of our data on #genetic risk of #atherosclerosis at #AHA25. @tulanemedicine.bsky.social
November 9, 2025 at 11:42 PM
Always great when we can introduce new folks to #vascular biology research. @AbboudFHassan doing a great job talking about some of our data on #genetic risk of #atherosclerosis at #AHA25. @tulanemedicine.bsky.social
Excellent work by Dr. Avik Sarkar @tulanemedicine.bsky.social on one of areas of emphasis in the my lab focusing on #vascular #senescence at #AHA25. Understanding why only some vascular beds get #atherosclerosis using #singlecellRNAseq to show protective transcripts in IMA @ahascience.bsky.social
November 9, 2025 at 1:12 PM
Excellent work by Dr. Avik Sarkar @tulanemedicine.bsky.social on one of areas of emphasis in the my lab focusing on #vascular #senescence at #AHA25. Understanding why only some vascular beds get #atherosclerosis using #singlecellRNAseq to show protective transcripts in IMA @ahascience.bsky.social
Excited for #AHA25 kicking off today in #NOLA! Looking forward to great #CVD #science, cutting edge #clinicaltrials and of course meeting old friends//making new ones. Have several posters/talks by students/trainees in the lab. Stop by & see what we are doing with #senescence and vascular/CVD.
November 7, 2025 at 2:04 PM
Excited for #AHA25 kicking off today in #NOLA! Looking forward to great #CVD #science, cutting edge #clinicaltrials and of course meeting old friends//making new ones. Have several posters/talks by students/trainees in the lab. Stop by & see what we are doing with #senescence and vascular/CVD.
Reposted by Amitabh C. Pandey
On our #LongCovid clinical trial launched today!
thesicktimes.org/2025/10/30/w... @julialmv.bsky.social @scripps.edu
thesicktimes.org/2025/10/30/w... @julialmv.bsky.social @scripps.edu
We need more at-home clinical trials for Long COVID. Here’s how we designed the largest one yet. - The Sick Times
We are now recruiting for the Long COVID Treatment Trial-Tirzepatide (LoCITT-T), which participants can complete entirely from bed.
thesicktimes.org
October 30, 2025 at 11:05 PM
On our #LongCovid clinical trial launched today!
thesicktimes.org/2025/10/30/w... @julialmv.bsky.social @scripps.edu
thesicktimes.org/2025/10/30/w... @julialmv.bsky.social @scripps.edu
Reposted by Amitabh C. Pandey
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics
www.nature.com/articles/s41...
www.nature.com/articles/s41...
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics - Nature Communications
Single-cell RNAseq can struggle to capture cellular heterogeneity due to the relatively low expression of biologically meaningful transcripts. Here the authors present an approach called scCLEAN, whic...
www.nature.com
May 30, 2025 at 12:53 PM
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Amitabh C. Pandey
Today the 1st case of CRISPR 3.0 (Prime genome editing) announced for a teenager with chronic granulomatous disease
www.nature.com/articles/d41...
www.nature.com/articles/d41...
May 19, 2025 at 1:51 PM
Today the 1st case of CRISPR 3.0 (Prime genome editing) announced for a teenager with chronic granulomatous disease
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Reposted by Amitabh C. Pandey
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics
->Nature | More info from EcoSearch
->Nature | More info from EcoSearch
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics
Research for this manuscript complies with all relevant ethical regulations and requirements. Human donor samples were de-identified for the entirety of the study, with no identifiable data given to study investigators. All studies of the human cells (PBMCs and VSMCs)...
www.nature.com
May 19, 2025 at 11:29 PM
Excited to share our latest work now online in @NatureComms. Detail a CRISPR/Cas9 based depletion in #scRNAseq. Depleting ubiquitous reads helps improve reads beyond that achieved with increased sequencing depth alone. Read more: rdcu.be/emJe6
@erictopol.bsky.social 1/
@erictopol.bsky.social 1/
A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics
Nature Communications - Single-cell RNAseq can struggle to capture cellular heterogeneity due to the relatively low expression of biologically meaningful transcripts. Here the authors present an...
rdcu.be
May 20, 2025 at 11:13 AM
Excited to share our latest work now online in @NatureComms. Detail a CRISPR/Cas9 based depletion in #scRNAseq. Depleting ubiquitous reads helps improve reads beyond that achieved with increased sequencing depth alone. Read more: rdcu.be/emJe6
@erictopol.bsky.social 1/
@erictopol.bsky.social 1/